Author | Conference | Journal | Organization | Year | DOI
Look for results that meet for the following criteria:
Academic
Publications
Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma

Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma,10.1007/s12156-010-0039-y,Oncology Reviews,Chiara PaglinoCam

Edit
Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma   (Citations: 3)
BibTex | RIS | RefWorks Download
With the recent development of targeted therapies (Sorafenib, Sunitinib, Temsirolimus, Bevacizumab plus Interferon-a, Everolimus and now also Pazopanib) patients with advanced renal cell carcinoma (RCC) now have a wide range of treatment options, all of which have shown both relevant clinical activity and manageable safety profile. This abundance of active treatments, coupled with relatively limited information, we have gathered from registrative phase III trials have raised the question of how to use these agents optimally. Indeed, since presently, a cure for advanced RCC is definitely out of sight—despite the improvements made so far—the goal of therapy should be to extend progressionfree survival (PFS) while maintaining a patient’s quality of life.
Journal: Oncology Reviews , vol. 4, no. 1, pp. 1-3, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
More »
Sort by:

Citations (3)

Share this on